nach oben

Current Treatment Options in Gastroenterology

12.03.2024

Barrett’s Esophagus: Who and How Do We Screen?

verfasst von: Bibek Saha, MD, Anjul Verma, MBBS, Prasad G. Iyer, MD, MS

Erschienen in: Current Treatment Options in Gastroenterology

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Barrett’s esophagus (BE) is the precursor of most Esophageal Adenocarcinomas (EACs) and progresses via the development of dysplasia. Hence BE screening is recommended by gastroenterology societies in patients with risk factors. Endoscopic surveillance enables the detection of dysplasia and early stage EAC, which can be treated successfully endoscopically, reducing the incidence and mortality of EAC. Despite these recommendations, only 10% of all EACs are detected in a surveillance program, and only a third or less of all BE cases are diagnosed.

Recent Findings

While cost associated with endoscopic screening is a barrier to screening those with risk factors, non-endoscopic cell-collection devices combined with biomarkers, namely Cytosponge-TFF3 and EsophaCap/EsoChek-MDM, are effective alternatives that may allow cost-effective screening in this population. Current guidelines which recommend screening in only those with GERD and other risk factors have been found to be poorly sensitive for BE and EAC given the substantial prevalence of BE in those without GERD. Hence several prediction models to enable the identification of those at risk for BE/EAC with moderate accuracy have been developed.

Summary

Future guidelines and risk prediction models for BE screening should include patients without GERD. BE prediction models encompassing multiple risk factors should be integrated into electronic health records to automatically identify patients at high risk. Cytosponge-TFF3 or EsophaCap/EsoChek-MDM, with subsequent diagnostic endoscopy in those with positive tests, can then be performed. Future studies to investigate whether this approach improves higher rates of BE/EAC screening and detection are warranted.

Shaheen NJ, Falk GW, Iyer PG, Souza RF, Yadlapati RH, Sauer BG, et al. Diagnosis and Management of Barrett’s Esophagus: An Updated ACG Guideline. Official journal of the American College of Gastroenterology | ACG. 2022;117:559–87.

2.••

Saha B, Vantanasiri K, Mohan BP, Goyal R, Garg N, Gerberi D, et al. Prevalence of Barrett’s Esophagus and Esophageal Adenocarcinoma With and Without Gastroesophageal Reflux: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023;S1542–3565(23):00848. A systematic review and meta-analysis highlighting that BE prevalence in those without GERD is substantial at 4.9% in large population-based studies.

3.••

Nguyen TH, Thrift AP, Rugge M, El-Serag HB. Prevalence of Barrett’s esophagus and performance of societal screening guidelines in an unreferred primary care population of U.S. veterans. Gastrointestinal Endoscopy. 2021;93:409–419.e1. A retrospective analysis of a prospective cross-sectional study that demonstrated that ACG, ASGE, ESGE, and BSG guidelines, which all have the presence of GERD as the primary criterion for screening, have low sensitivities and only modest specificities for BE screening. In contrast, AGA guidelines that do not require GERD, was found to have a low specificity for BE screening.

Coleman HG, Xie S-H, Lagergren J. The Epidemiology of Esophageal Adenocarcinoma. Gastroenterology. 2018;154:390–405.CrossRefPubMed

Taylor JB, Rubenstein JH. Meta-Analyses of the Effect of Symptoms of Gastroesophageal Reflux on the Risk of Barrett’s Esophagus. Am J Gastroenterol. 2010;105:1730–7.CrossRefPubMedCentral

Hamade N, Vennelaganti S, Parasa S, Vennalaganti P, Gaddam S, Spaander MCW, et al. Lower Annual Rate of Progression of Short-Segment vs Long-Segment Barrett’s Esophagus to Esophageal Adenocarcinoma. Clin Gastroenterol Hepatol. 2019;17:864–8.CrossRefPubMed

Solanky D, Krishnamoorthi R, Crews N, Johnson M, Wang K, Wolfsen H, et al. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma. J Clin Gastroenterol. 2019;53:361–5.CrossRefPubMed

8.••

Stewart M, Menon A, Akbar U, Garg S, Jang HJ, Trindade AJ. Missed opportunities to screen for Barrett’s esophagus in the primary care setting of a large health system. Gastrointest Endosc. 2023;98:162–9. This study utilized an algorithm to identify primary care patients at high-risk for BE and demonstrated that only 30% of these patients were screened for BE in clinical practice.CrossRefPubMed

9.•

Eluri S, Reddy S, Ketchem CC, Tappata M, Nettles HG, Watts AE, et al. Low Prevalence of Endoscopic Screening for Barrett’s Esophagus in a Screening-Eligible Primary Care Population. Am J Gastroenterol. 2022;117:1764–71. This study of a primary care population demonstrated that only 39% of screening-eligible patients had undergone screening EGD.CrossRefPubMedPubMedCentral

10.

Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon LF, et al. Prediction of Barrett’s Esophagus Among Men. Am J Gastroenterol. 2013;108:353–62.CrossRefPubMedPubMedCentral

11.

Kamboj AK, Katzka DA, Iyer PG. Endoscopic Screening for Barrett’s Esophagus and Esophageal Adenocarcinoma. Gastrointest Endosc Clin N Am. 2021;31:27–41.CrossRefPubMed

12.

Jankowski JAZ, de Caestecker J, Love SB, Reilly G, Watson P, Sanders S, et al. Esomeprazole and aspirin in Barrett’s oesophagus (AspECT): a randomised factorial trial. Lancet. 2018;392:400–8.CrossRefPubMedPubMedCentral

13.

Li L, Cao Z, Zhang C, Pan W. Risk of esophageal adenocarcinoma in patients with Barrett’s esophagus using proton pump inhibitors: a systematic review with meta-analysis and sequential trial analysis. Translational Cancer Research [Internet]. 2021 [cited 2023 Dec 20];10. Available from: https://tcr.amegroups.org/article/view/51405

14.

State of the Art: Management of Barrett’s Esophagus Related Dysplasia and Neoplasia—Which Patient and What Therapy? - Lovekirat Dhaliwal, Prasad G. Iyer, 2021 [Internet]. [cited 2023 Dec 19]. Available from: https://journals.sagepub.com/doi/full/https://doi.org/10.1177/2634516121993260

15.

Shaheen NJ, Sharma P, Overholt BF, Wolfsen HC, Sampliner RE, Wang KK, et al. Radiofrequency Ablation in Barrett’s Esophagus with Dysplasia. N Engl J Med. 2009;360:2277–88.CrossRefPubMed

16.

Phoa KN, Van Vilsteren FGI, Weusten BLAM, Bisschops R, Schoon EJ, Ragunath K, et al. Radiofrequency Ablation vs Endoscopic Surveillance for Patients With Barrett Esophagus and Low-Grade Dysplasia: A Randomized Clinical Trial. JAMA. 2014;311:1209.CrossRefPubMed

17.

Prasad GA, Wu TT, Wigle DA, Buttar NS, Wongkeesong L-M, Dunagan KT, et al. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterol. 2009;137:815–23.CrossRef

18.

Codipilly DC, Chandar AK, Singh S, Wani S, Shaheen NJ, Inadomi JM, et al. The Effect of Endoscopic Surveillance in Patients With Barrett’s Esophagus: A Systematic Review and Meta-analysis. Gastroenterology. 2018;154:2068-2086.e5.CrossRefPubMed

19.

Muthusamy VR, Wani S, Gyawali CP, Komanduri S. AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review. Clin Gastroenterol Hepatol. 2022;20:2696-2706.e1.CrossRefPubMedPubMedCentral

20.

ASGE STANDARDS OF PRACTICE COMMITTEE, Qumseya B, Sultan S, Bain P, Jamil L, Jacobson B, et al. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. 2019;90:335–359.e2.

21.

Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang J-Y, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMed

22.

Weusten BLAM, Bisschops R, Dinis-Ribeiro M, di Pietro M, Pech O, Spaander MCW, et al. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2023;55:1124–46.CrossRefPubMed

23.•

Chandar AK, Low EE, Singer ME, Yadlapati R, Singh S. Estimated Burden of Screening for Barrett’s Esophagus in the United States. Gastroenterol. 2023;S0016–5085(23):00537–41. Estimated the total number of screen-eligible patients for BE in the United States based on four different Gastroenterology guidelines.

24.•

Sami SS, Moriarty JP, Rosedahl JK, Borah BJ, Katzka DA, Wang KK, et al. Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett’s Esophagus Screening. Am J Gastroenterol. 2021;116:1620–31. This study utilized Markov modeling to investigate the costs of BE screening, utilizing various screening modalities including non-endoscopic tools, in those with and without GERD. They discovered that non-endoscopic cell-collection devices combined with biomarkers were cost-effective regardless of GERD status and were the optimal screening modalities in all modelling scenarios.CrossRefPubMedPubMedCentral

25.

Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM. Esophageal Adenocarcinoma Incidence in Individuals With Gastroesophageal Reflux: Synthesis and Estimates From Population Studies. Am J Gastroenterol. 2011;106:254.CrossRefPubMed

26.••

Sawas T, Zamani SA, Killcoyne S, Dullea A, Wang KK, Iyer PG, et al. Limitations of Heartburn and Other Societies’ Criteria in Barrett’s Screening for Detecting De Novo Esophageal Adenocarcinoma. Clin Gastroenterol Hepatol. 2021;S1542–3565(21):01152–6. Investigated American and British EAC cohorts, and demonstrated that the ACG and BSG screening criteria, which utilize chronic GERD as the major screening criterion, were not able to identify 54.9% and 38.9% of EAC cases, respectively.

27.

Wenker TN, Tan MC, Liu Y, El-Serag HB, Thrift AP. Prior Diagnosis of Barrett’s Esophagus Is Infrequent, but Associated with Improved Esophageal Adenocarcinoma Survival. Dig Dis Sci. 2018;63:3112–9.CrossRefPubMed

28.

Tan MC, Mansour N, White DL, Sisson A, El-Serag HB, Thrift AP. Systematic review with meta-analysis: Prevalence of prior and concurrent Barrett’s oesophagus in oesophageal adenocarcinoma patients. Aliment Pharmacol Ther. 2020;52:20–36.CrossRefPubMedPubMedCentral

29.

Rubenstein JH, Thrift AP. Risk factors and populations at risk: Selection of patients for screening for Barrett’s oesophagus. Best Pract Res Clin Gastroenterol. 2015;29:41–50.CrossRefPubMed

30.

Gerson LB, Edson R, Lavori PW, Triadafilopoulos G. Use of a simple symptom questionnaire to predict Barrett’s esophagus in patients with symptoms of gastroesophageal reflux. Am J Gastroenterol. 2001;96:2005–12.CrossRefPubMed

31.

Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? Gastrointest Endosc. 2003;58:661–70.CrossRefPubMed

32.

Thrift AP, Kendall BJ, Pandeya N, Vaughan TL, Whiteman DC, Health for the S of D. A clinical risk prediction model for Barrett’s esophagus. Cancer prevention research (Philadelphia, Pa). 2012;5:1115.

33.

Xie S-H, Ness-Jensen E, Medefelt N, Lagergren J. Assessing the feasibility of targeted screening for esophageal adenocarcinoma based on individual risk assessment in a population-based cohort study in Norway (The HUNT Study). Am J Gastroenterol. 2018;113:829–35.CrossRefPubMed

34.

Kunzmann AT, Thrift AP, Cardwell CR, Lagergren J, Xie S, Johnston BT, et al. Model for Identifying Individuals at Risk for Esophageal Adenocarcinoma. Clin Gastroenterol Hepatol. 2018;16:1229-1236.e4.CrossRefPubMed

35.

Liu X, Wong A, Kadri SR, Corovic A, O’Donovan M, Lao-Sirieix P, et al. Gastro-Esophageal Reflux Disease Symptoms and Demographic Factors as a Pre-Screening Tool for Barrett’s Esophagus. PLoS ONE. 2014;9:e94163.ADSCrossRefPubMedPubMedCentral

36.

Tan WK, Sharma AN, Chak A, Fitzgerald RC. Progress in Screening for Barrett’s Esophagus: Beyond Standard Upper Endoscopy. Gastrointest Endosc Clin N Am. 2021;31:43–58.CrossRefPubMed

37.

Rubenstein JH, McConnell D, Waljee AK, Metko V, Nofz K, Khodadost M, et al. Validation and Comparison of Tools for Selecting Individuals to Screen for Barrett’s Esophagus and Early Neoplasia. Gastroenterology. 2020;158:2082–92.CrossRefPubMed

38.

Murphy DR, Meyer AN, Sittig DF, Meeks DW, Thomas EJ, Singh H. Application of electronic trigger tools to identify targets for improving diagnostic safety. BMJ Qual Saf. 2019;28:151–9.CrossRefPubMed

39.•

Iyer PG, Sachdeva K, Leggett CL, Codipilly DC, Abbas H, Anderson K, et al. Development of Electronic Health Record-Based Machine Learning Models to Predict Barrett’s Esophagus and Esophageal Adenocarcinoma Risk. Clin Transl Gastroenterol. 2023;14:e00637. In this study, an AI powered ML BE/EAC risk prediction algorithm was designed utilizing conventional risk factors and additional novel factors for BE/EAC. This algorithm determined BE/EAC risk at least one year before diagnosis, from a large deidentified EHR database, with improved accuracy (AUC 0.84) compared with conventional risk factor-based risk scores.CrossRefPubMedPubMedCentral

40.•

Rubenstein JH, Fontaine S, MacDonald PW, Burns JA, Evans RR, Arasim ME, et al. Predicting Incident Adenocarcinoma of the Esophagus or Gastric Cardia Using Machine Learning of Electronic Health Records. Gastroenterology. 2023;165:1420-1429.e10. This study developed the K-ECAN tool, a novel method for predicting EAC using EHR data from the VA database. This tool utilized ML, and outperformed established models including the HUNT tool and Kunzmann model, as well as published guidelines.CrossRefPubMed

41.

Kendall BJ, Rubenstein JH, Cook MB, Vaughan TL, Anderson LA, Murray LJ, et al. Inverse Association Between Gluteofemoral Obesity and Risk of Barrett’s Esophagus in a Pooled Analysis. Clin Gastroenterol Hepatol. 2016;14:1412-1419.e3.CrossRefPubMedPubMedCentral

42.

Singh S, Sharma AN, Murad MH, Buttar NS, El-Serag HB, Katzka DA, et al. Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1399-1412.e7.CrossRefPubMed

43.

Khandwalla HE, Graham DY, Kramer JR, Ramsey DJ, Duong N, Green LK, et al. Barrett’s Esophagus Suspected at Endoscopy but No Specialized Intestinal Metaplasia on Biopsy, What’s Next? Am J Gastroenterol. 2014;109:178–82.ADSCrossRefPubMed

44.

Codipilly DC, Iyer PG. Novel Screening Tests for Barrett’s Esophagus. Curr Gastroenterol Rep. 2019;21:42.CrossRefPubMed

45.

Peery AF, Hoppo T, Garman KS, Dellon ES, Daugherty N, Bream S, et al. Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc. 2012;75:945-953.e2.CrossRefPubMedPubMedCentral

46.

Sami SS, Subramanian V, Ortiz-Fernández-Sordo J, Saeed A, Singh S, Guha IN, et al. Performance characteristics of unsedated ultrathin video endoscopy in the assessment of the upper GI tract: systematic review and meta-analysis. Gastrointest Endosc. 2015;82:782–92.CrossRefPubMed

47.

Blevins CH, Egginton JS, Shah ND, Johnson ML, Iyer PG. Comparative Assessment of Patient Preferences and Tolerability in Barrett Esophagus Screening: Results From a Randomized Trial. J Clin Gastroenterol. 2018;52:880.CrossRefPubMedPubMedCentral

48.

Shariff MK, Varghese S, O’Donovan M, Abdullahi Z, Liu X, Fitzgerald RC, et al. Pilot randomized crossover study comparing the efficacy of transnasal disposable endosheath with standard endoscopy to detect Barrett’s esophagus. Endoscopy. 2016;48:110–6.PubMed

49.

Strauss AL, Falk GW. New Techniques to Screen for Barrett Esophagus. Gastroenterol Hepatol (N Y). 2023;19:383–90.PubMed

50.

Sami SS, Ragunath K, Iyer PG. Screening for Barrett’s Esophagus and Esophageal Adenocarcinoma: Rationale, Recent Progress, Challenges and Future Directions. Clin Gastroenterol Hepatol. 2015;13:623–34.CrossRefPubMed

51.

Rodriguez SA, Banerjee S, Desilets D, Diehl DL, Farraye FA, Kaul V, et al. Ultrathin endoscopes. Gastrointest Endosc. 2010;71:893–8.CrossRefPubMed

52.

Sami SS, Iyer PG. Recent Advances in Screening for Barrett’s Esophagus. Curr Treat Options Gastro. 2018;16:1–14.CrossRef

53.

Sami SS, Dunagan KT, Johnson ML, Schleck CD, Shah ND, Zinsmeister AR, et al. A randomized comparative effectiveness trial of novel endoscopic techniques and approaches for Barrett’s esophagus screening in the community. Am J Gastroenterol. 2015;110:148–58.CrossRefPubMed

54.

Moriarty JP, Shah ND, Rubenstein JH, Blevins CH, Johnson M, Katzka DA, et al. Costs associated with Barrett’s esophagus screening in the community: an economic analysis of a prospective randomized controlled trial of sedated versus hospital unsedated versus mobile community unsedated endoscopy. Gastrointest Endosc. 2018;87:88-94.e2.CrossRefPubMed

55.

Park J, Cho YK, Kim JH. Current and Future Use of Esophageal Capsule Endoscopy. Clin Endosc. 2018;51:317–22.CrossRefPubMedPubMedCentral

56.

Bhardwaj A, Hollenbeak CS, Pooran N, Mathew A. A meta-analysis of the diagnostic accuracy of esophageal capsule endoscopy for Barrett’s esophagus in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2009;104:1533–9.CrossRefPubMed

57.

Rubenstein JH, Inadomi JM, Brill JV, Eisen GM. Cost utility of screening for Barrett’s esophagus with esophageal capsule endoscopy versus conventional upper endoscopy. Clin Gastroenterol Hepatol. 2007;5:312–8.CrossRefPubMed

58.

Bell MG, Iyer PG. Innovations in Screening Tools for Barrett’s Esophagus and Esophageal Adenocarcinoma. Curr Gastroenterol Rep. 2021;23:22.CrossRefPubMed

59.

Beg S, Card T, Warburton S, Rahman I, Wilkes E, White J, et al. Diagnosis of Barrett’s esophagus and esophageal varices using a magnetically assisted capsule endoscopy system. Gastrointest Endosc. 2020;91:773-781.e1.CrossRefPubMed

60.

Yusuf A, Fitzgerald RC. Screening for Barrett’s Oesophagus: Are We Ready for it? Curr Treat Options Gastro. 2021;19:321–36.CrossRef

61.

Fitzgerald RC, di Pietro M, O’Donovan M, Maroni R, Muldrew B, Debiram-Beecham I, et al. Cytosponge-trefoil factor 3 versus usual care to identify Barrett’s oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial. Lancet. 2020;396:333–44.CrossRefPubMedPubMedCentral

62.

Heberle CR, Omidvari A-H, Ali A, Kroep S, Kong CY, Inadomi JM, et al. Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett’s Esophagus With a Minimally Invasive Cell Sampling Device. Clin Gastroenterol Hepatol. 2017;15:1397-1404.e7.CrossRefPubMedPubMedCentral

63.

Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med. 2015;12:e1001780.CrossRefPubMedPubMedCentral

64.

Iyer PG, Taylor WR, Johnson ML, Lansing RL, Maixner KA, Hemminger LL, et al. Accurate Nonendoscopic Detection of Barrett’s Esophagus by Methylated DNA Markers: A Multisite Case Control Study. Am J Gastroenterol. 2020;115:1201–9.CrossRefPubMedPubMedCentral

65.••

Iyer PG, Taylor WR, Slettedahl SW, Lansing RL, Hemminger LL, Cayer FK, et al. Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett’s esophagus in a multisite case-control study. Gastrointest Endosc. 2021;94:498–505. (In this multi-center case-control study, the researchers validated the 5-MDM BE maker panel for EsophaCap. They demonstrated a strong sensitivity and specificity of ≥90% with respect to BE detection, as well as a good safety profile and tolerability. They also developed 3-MDM marker models using the 5 original markers and showed the sensitivity and specificity for BE detection to be similar to the 5-MDM panel.)CrossRefPubMedPubMedCentral

66.

Wang Z, Kambhampati S, Cheng Y, Ma K, Simsek C, Tieu AH, et al. Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett’s Esophagus: A Prospective Validation Study. Clin Cancer Res. 2019;25:2127–35.CrossRefPubMedPubMedCentral

67.

Krishna Chandar A, Sharma A, Chak A. Novel Screening Alternatives for Barrett Esophagus. Gastroenterol Hepatol (N Y). 2020;16:238–45.PubMed

68.

Moinova HR, LaFramboise T, Lutterbaugh JD, Chandar AK, Dumot J, Faulx A, et al. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett’s esophagus. Sci Transl Med. 2018;10:eaao5848.

69.

Chandar AK, Alaber O, Dumot JA, Faulx AL, Brock W, Thota PN, et al. Mo1170 Modifications in non-endoscopic distal esophagus sampling devices improve ability to swallow and dna yield. Gastrointestinal Endoscopy. 2019;89:AB448.

70.

Krilaviciute A, Heiss JA, Leja M, Kupcinskas J, Haick H, Brenner H. Detection of cancer through exhaled breath: a systematic review. Oncotarget. 2015;6:38643–57.CrossRefPubMedPubMedCentral

71.

Peters Y, Schrauwen RWM, Tan AC, Bogers SK, de Jong B, Siersema PD. Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device. Gut. 2020;69:1169–72.CrossRefPubMed

72.

Cabibi D, Caruso S, Bazan V, Castiglia M, Bronte G, Ingrao S, et al. Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus. Oncotarget. 2016;7:47821–30.CrossRefPubMedPubMedCentral

73.

Clark RJ, Craig MP, Agrawal S, Kadakia M. microRNA involvement in the onset and progression of Barrett’s esophagus: a systematic review. Oncotarget. 2018;9:8179–96.CrossRefPubMedPubMedCentral

74.

Craig MP, Rajakaruna S, Paliy O, Sajjad M, Madhavan S, Reddy N, et al. Differential MicroRNA Signatures in the Pathogenesis of Barrett’s Esophagus. Clin Transl Gastroenterol. 2020;11:e00125.CrossRefPubMedPubMedCentral

75.

Mallick R, Patnaik SK, Wani S, Bansal A. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett’s Esophagus. Dig Dis Sci. 2016;61:1039–50.CrossRefPubMed

76.

Bus P, Kestens C, Ten Kate FJW, Peters W, Drenth JPH, Roodhart JML, et al. Profiling of circulating microRNAs in patients with Barrett’s esophagus and esophageal adenocarcinoma. J Gastroenterol. 2016;51:560–70.CrossRefPubMed

77.

Wang L, Ji F, Liu G, Wang W, Li Z, Yue Y, et al. Upregulation of circulating miR130a is correlated with development of Barrett’s esophagus and esophageal adenocarcinoma. Onco Targets Ther. 2019;12:1–7.CrossRefPubMed

78.

Otaki F, Ma GK, Krigel A, Dierkhising RA, Lewis JT, Blevins CH, et al. Outcomes of patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study. Gastrointest Endosc. 2020;92:31-39.e1.CrossRefPubMedPubMedCentral

Titel: Barrett’s Esophagus: Who and How Do We Screen?
verfasst von: Bibek Saha, MD
Anjul Verma, MBBS
Prasad G. Iyer, MD, MS
Publikationsdatum: 12.03.2024
Verlag: Springer US
Erschienen in: Current Treatment Options in Gastroenterology
Print ISSN: 1092-8472
Elektronische ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-024-00441-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen